Kevin D. McCormick;Younong Yu;Robert George Aslanian;Jun Qin;Ashwin Umesh Rao;Anandan Palani;Xiao Chen;Jie Wu;Sylvia Joanna Degrado;Robert D. Mazzola, JR.;Christopher W. Boyce;Phieng Silipha;Dong Xiao
发明人:
Christopher W. Boyce,Sylvia Joanna Degrado,Xiao Chen,Jun Qin,Robert D. Mazzola, JR.,Younong Yu,Kevin D. McCormick,Anandan Palani,Dong Xiao,Robert George Aslanian,Jie Wu,Ashwin Umesh Rao,Phieng Silipha
申请号：
US13996361
公开号：
US20130303517A1
申请日:
2011.12.19
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J1, J2, R1, R2, R3, R22, Ra, Rb, Rc, Rd, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.
